Navigation Links
Drs. Robert Lanza and Kwang-Soo Kim Win Prestigious NIH Director's Award
Date:9/22/2010

MARLBOROUGH, Mass., Sept. 22 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ACTC)  announced today that the company's Chief Scientific Officer, Robert Lanza, MD, and Kwang-Soo Kim, PhD, of Harvard University and McLean Hospital, have won a National Institutes of Health (NIH) Director's Opportunity Award for research in "Translating Basic Science Discoveries into New and Better Treatments" under the American Recovery & Reinvestment Act of 2009. The NIH Award provides McLean Hospital and ACT's joint venture with CHA Biotech, Stem Cell & Regenerative Medicine International (SCRMI), $1.9 million to explore the potential of protein-induced pluripotent stem (iPS) cells as a source of universal red blood cells and platelets for transfusion.

The research, which will include a team led by Shi-Jiang Lu, PhD, MPH, Senior Director at SCRMI, aims to establish and characterize clinically viable iPS cells from healthy O Rh-negative (O-) subjects by direct delivery of reprogramming proteins without the use of viruses or foreign-DNA and to explore the potential of iPSC's as a source of universal red blood cells (RBCs) and platelets for transfusion.  The limited supply of RBC and platelets is a serious medical issue that can have potentially life-threatening consequences, especially for patients where multiple transfusions are necessary. The low prevalence of O negative 'universal donor' blood type in the general population (<8% in Western countries and <1% in Asia) further intensifies the consequences of blood shortages for emergency situations where blood supply and typing is limited.  

Human iPS cells offer the possibility to generate a non-controversial source of patient-specific stem cells without destruction of embryos.  However, current iPS cells suffer from major drawbacks that may cause unpredictable genetic dysfunction and tumor formation.  This award aims to bypass these problems and establish an efficient and safe way of reprogramming adult tissues into stem cells using proteins. It will also address whether they can be expanded indefinitely as an unlimited source of patient-specific and universal donor blood cells and platelets.

"We congratulate Drs. Lanza and Kim for receiving this prestigious NIH award," said William M. Caldwell IV, Chairman and CEO of ACT.  "Although iPS cell technology has enormous potential for biomedical research and cell-based therapy, it is still in its early stage and significant obstacles must be overcome in order to realize its full potential.  We at ACT have been at the forefront of this technology well before the term 'iPS' was even coined, and in particular have been involved in identifying and solving those issues that stand between research and actual therapies. I am confident that Drs. Lanza and Kim will continue to make great strides towards making iPS-derived therapies a reality."

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2009.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.


'/>"/>
SOURCE Advanced Cell Technology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Present at Robert W. Baird & Co. 2010 Health Care Conference
2. Ruedi Waeger Receives the 2010 Robert W. Reilly Leadership Award from Plasma Protein Therapeutics Association
3. Alison Martin, MD and Robert W. Malone, MD Join Beardsworth
4. Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors
5. Advanced Cell Technologys Chief Scientific Officer, Robert Lanza, Opening Plenary Speaker at the 3rd International Conference on Cell Therapy
6. Organovo Appoints Robert Baltera to Board
7. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
8. Dr. Robert Lanza Featured on Michio Kakus Explorations in Science
9. Accuray Incorporated to Present at Robert Baird 2009 Healthcare Conference
10. Kendle to Present at Robert Baird 2009 Health Care Conference
11. PAREXEL International to Present at Robert Baird 2009 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 25, 2017 , ... ... services that are necessary in the preparation and development of human cells and ... operates under the US Food and Drug Administration’s (FDA) Current Good Manufacturing Practices ...
(Date:7/26/2017)... ... July 26, 2017 , ... DuPont Pioneer ... of crop productivity and economics for the food, feed and biofuel industries, announced ... agreement includes the research and development of microbiome-based seed treatments in corn. The ...
(Date:7/25/2017)... , ... July 25, 2017 , ... ... enhance the microbiome and improve efficiency of livestock farming while reducing the use ... has licensed additional intellectual property from Cornell University. , These new proprietary ...
(Date:7/24/2017)... FL (PRWEB) , ... July ... ... Strategic Analyst, Kenny Soulstring, today announced that the stock market news outlet ... in risk assessment diagnostic testing that screens and identifies exposure, progression and ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
Breaking Biology News(10 mins):